Onconetix, Inc. Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax
Onconetix, Inc. (ONCO) reported Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax of $127.52 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax · last filed 2026-08-13
- Onconetix, Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2026-06-30 was $127.52K.
- Onconetix, Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2026-03-31 was $210.17K.
- Onconetix, Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2025-12-31 was -$1.31M, a 133.25% decline year-over-year.
- Onconetix, Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2025-09-30 was $502.65K.
- Onconetix, Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2025 was -$2.83M, a 153.05% decline from fiscal 2024.
- Onconetix, Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2024 was $5.34M.
- Onconetix, Inc. other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2023 was -$2.37M.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 3 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 6 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 9 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $127.52K 10-Q · filed 2026-08-13 | $337.69K 10-Q · filed 2026-08-13 | -$975.62K derived: sum of 3 quarters · filed 2026-08-13 | -$472.97K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $210.17K 10-Q · filed 2026-05-13 | -$1.10M derived: sum of 2 quarters · filed 2026-05-13 | -$600.49K derived: sum of 3 quarters · filed 2026-05-13 | -$2.48M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | -$810.66K derived: sum of 2 quarters · filed 2026-03-13 | -$2.69M derived: sum of 3 quarters · filed 2026-08-13 | -$2.83M 10-K · filed 2026-03-13 |
| 2025-09-30 | $502.65K 10-Q · filed 2025-11-13 | -$1.38M derived: sum of 2 quarters · filed 2026-08-13 | -$1.52M 10-Q · filed 2025-11-13 | $2.43M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$1.88M 10-Q · filed 2026-08-13 | -$2.02M 10-Q · filed 2026-08-13 | $1.93M derived: sum of 3 quarters · filed 2026-08-13 | -$1.56M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$141.05K 10-Q · filed 2026-05-13 | $3.81M derived: sum of 2 quarters · filed 2026-05-13 | $320.13K derived: sum of 3 quarters · filed 2026-05-13 | $210.13K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $3.95M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-13 | $461.18K derived: sum of 2 quarters · filed 2026-03-13 | $351.18K derived: sum of 3 quarters · filed 2026-03-13 | $5.34M 10-K · filed 2026-03-13 |
| 2024-09-30 | -$3.49M 10-Q · filed 2025-11-13 | -$3.60M derived: sum of 2 quarters · filed 2025-11-13 | $1.39M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | -$110.00K 10-Q · filed 2025-08-14 | $4.88M 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $4.99M 10-Q · filed 2025-06-12 | |||
| 2023-12-31 | -$2.37M 10-K · filed 2025-06-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |